Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNYBiotechnology
-$6.27 today
- Market cap
- $20.01B
- Beta
- 0.27
- P/E (TTM)
- 63.6
- EPS (TTM)
- $4.34
Volume 2.52M
Average 1.11M
ALNY Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY
Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026
Change in working capital dips below year-ago levels
Q2 FY2026 change in working capital of $30.3M fell 39.5% year over year, behind the +151.5% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +132.1% a year.
Context
- Change in working capital amounted to 12.0% of revenue in FY2025, up 2.5 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -39.5% toward the trailing-twelve-month pace of +151.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (444.78M) USD
- Year-over-year change
- -107.8%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (444.78M) | -107.8% |
| FY2024 | 2024-12-31 | (214.08M) | -2089.8% |
| FY2023 | 2023-12-31 | 10.76M | +130.3% |
| FY2022 | 2022-12-31 | (35.55M) | +78.2% |
| FY2021 | 2021-12-31 | (162.82M) | — |
Change in Working Capital vs competitors
How ALNY compares with its peers on the latest reported figures
- ALNY's LTM Jun 2026 change in working capital of $529.22M is the largest of the 6 companies compared; the peer median is $38.08M.
- Its year-over-year change of +151.5% is the 4th highest of 5, against a peer median of +182.4%.
- Change in working capital amounts to 11.0% of revenue for ALNY, versus a peer median of 53.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $529.22M | +151.5% | +132.1% | 11.0% | |
| LTM Sep 2026 | $160.4M | +161.3% | — | 16.7% | |
| LTM Sep 2026 | $71.69M | +493.1% | — | 15.9% | |
| LTM Mar 2026 | $52.13M | +203.5% | +11.0% | 78.9% | |
| LTM Mar 2026 | $38.08M | -58.7% | — | 53.0% | |
| LTM Mar 2026 | $5.6M | — | — | 607.2% | |
| Peer median (excluding ALNY) | $38.08M | +182.4% | +11.0% | 53.0% | |
Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (852.82M) | (1.13B) | (440.24M) | (278.16M) | 313.75M |
| Depreciation & Amortization | 47.57M | 44.47M | 54.05M | 56.67M | 55.66M |
| Deferred Income Tax | (55.7M) | 0 | 0 | (106.76M) | (2.2M) |
| Stock-Based Compensation | 165.72M | 230.65M | 221.68M | 272.08M | 348.24M |
| Change in Working Capital | (162.82M) | (35.55M) | 10.76M | (214.08M) | (444.78M) |
| Accounts Receivables | (101.8M) | (45.6M) | (87.94M) | (86.55M) | (359.96M) |
| Inventory | (26.42M) | (34.14M) | 18.37M | 13.59M | 8.47M |
| Accounts Payables | 88.24M | 191.77M | 80.84M | 91.09M | 75.07M |
| Other Working Capital | (122.85M) | (147.59M) | (509K) | (232.22M) | (168.36M) |
| Other Non-Cash Items | 216.37M | 350.32M | 257.91M | 261.94M | 253.42M |
| Operating Cash Flow | (641.69M) | (541.27M) | 104.16M | (8.31M) | 524.08M |
| Capital Expenditures | (76.37M) | (72.06M) | (62.21M) | (34.28M) | (58.7M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.66B) | (1.98B) | (1.82B) | (1.71B) | (1.36B) |
| Sales of Investments | 1.46B | 2.23B | 1.55B | 1.57B | 1.8B |
| Other Investing Activities | (4.36M) | (13.19M) | (4.44M) | 57.76M | 57.63M |
| Investing Cash Flow | (273.3M) | 169.35M | (336.35M) | (116.84M) | 436.33M |
| Debt Repayment | 500M | 254M | 0 | 0 | (546.95M) |
| Common Stock Issued | 246.27M | 259.36M | 147.46M | 302.95M | 250.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 500.85M | (87.61M) | 24.67M | (8.79M) | (8.27M) |
| Financing Cash Flow | 1.25B | 425.75M | 172.13M | 294.16M | (305.19M) |
| Effect of Forex Changes | (9.02M) | (7.43M) | 6.39M | (15.24M) | 34.94M |
| Net Change in Cash | 323.11M | 46.4M | (53.67M) | 153.77M | 690.16M |
| Free Cash Flow | (718.07M) | (613.33M) | 41.95M | (42.59M) | 465.38M |
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
Intrinsic Alpha fair value
Locked
Current Price
$149.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.